MARKET

SCYX

SCYX

Scynexis
NASDAQ
2.200
-0.020
-0.90%
After Hours: 2.150 -0.05 -2.27% 17:33 07/12 EDT
OPEN
2.270
PREV CLOSE
2.220
HIGH
2.289
LOW
2.080
VOLUME
169.45K
TURNOVER
0
52 WEEK HIGH
3.870
52 WEEK LOW
1.350
MARKET CAP
83.12M
P/E (TTM)
1.093
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SCYX last week (0701-0705)?
Weekly Report · 6d ago
Weekly Report: what happened at SCYX last week (0624-0628)?
Weekly Report · 07/01 09:38
Weekly Report: what happened at SCYX last week (0617-0621)?
Weekly Report · 06/24 09:40
Weekly Report: what happened at SCYX last week (0610-0614)?
Weekly Report · 06/17 09:37
Weekly Report: what happened at SCYX last week (0603-0607)?
Weekly Report · 06/10 09:38
Weekly Report: what happened at SCYX last week (0527-0531)?
Weekly Report · 06/03 09:39
Weekly Report: what happened at SCYX last week (0520-0524)?
Weekly Report · 05/27 09:40
Weekly Report: what happened at SCYX last week (0513-0517)?
Weekly Report · 05/20 09:39
More
About SCYX
SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.

Webull offers SCYNEXIS Inc stock information, including NASDAQ: SCYX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCYX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SCYX stock methods without spending real money on the virtual paper trading platform.